Abstract
Meganucleases are sequence-specific endonucleases recognizing large ( > 12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new applications, including therapeutic ones: redesigned endonucleases cleaving chosen sequences could be used to in gene therapy to correct mutated genes or introduce transgenes in chosen loci. Such “targeted” approaches markedly differ from current gene therapy strategies based on the random insertion of a complementing virus-borne transgene. As a consequence, they should bypass the odds of random insertion. Artificial fusion proteins including Zinc-Finger binding domains have provided important proofs of concept, however the toxicity of these proteins is still an issue. Today custom-designed homing endonucleases, the natural meganucleases, could represent an efficient alternative. After a brief description of the origin of the technology, current systems based on redesigned endonucleases will be presented, with a special emphasis on the recent advances in homing endonuclease engineering. Finally, we will discuss the main issues that will need to be addressed in order to bring this promising technology to the patient.
Keywords: I-SceI, I-CreI, ZFNs, homing endonucleases, gene correction, gene insertion, protein engineering, genome engineering, gene therapy, genome surgery
Current Gene Therapy
Title: Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy
Volume: 7 Issue: 1
Author(s): Frederic Paques and Philippe Duchateau
Affiliation:
Keywords: I-SceI, I-CreI, ZFNs, homing endonucleases, gene correction, gene insertion, protein engineering, genome engineering, gene therapy, genome surgery
Abstract: Meganucleases are sequence-specific endonucleases recognizing large ( > 12 bp) sequence sites and several laboratories have used these proteins to induce highly efficient gene targeting in mammalian cells. The recent development of artificial endonucleases with tailored specificities has opened the door for a wide range of new applications, including therapeutic ones: redesigned endonucleases cleaving chosen sequences could be used to in gene therapy to correct mutated genes or introduce transgenes in chosen loci. Such “targeted” approaches markedly differ from current gene therapy strategies based on the random insertion of a complementing virus-borne transgene. As a consequence, they should bypass the odds of random insertion. Artificial fusion proteins including Zinc-Finger binding domains have provided important proofs of concept, however the toxicity of these proteins is still an issue. Today custom-designed homing endonucleases, the natural meganucleases, could represent an efficient alternative. After a brief description of the origin of the technology, current systems based on redesigned endonucleases will be presented, with a special emphasis on the recent advances in homing endonuclease engineering. Finally, we will discuss the main issues that will need to be addressed in order to bring this promising technology to the patient.
Export Options
About this article
Cite this article as:
Paques Frederic and Duchateau Philippe, Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy, Current Gene Therapy 2007; 7 (1) . https://dx.doi.org/10.2174/156652307779940216
DOI https://dx.doi.org/10.2174/156652307779940216 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone
Cardiovascular & Hematological Disorders-Drug Targets Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research Targeting Angiogenesis in Soft Tissue Sarcomas
Current Angiogenesis (Discontinued) Recent Progresses in Application of Fullerenes in Cosmetics
Recent Patents on Biotechnology Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry FbD Supported Development and In Vitro Evaluation of Carbomer based Resveratrol Loaded Topical Antipsoriatic Nanoemulgel for its Targeted Skin Delivery
Pharmaceutical Nanotechnology Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets Anatomical Approach to Clinical Problems of Popliteal Fossa
Current Rheumatology Reviews Glucan Particles Loaded with Fluorinated Emulsions: A Sensitivity Improvement for the Visualization of Phagocytic Cells by <sup>19</sup>F-MRI
Current Molecular Imaging (Discontinued) Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine An Update on the Recent Advances in Cubosome: A Novel Drug Delivery System
Current Drug Metabolism Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Integrated Therapeutic Approaches in Head and Neck Cancer: The Importance of Multidisciplinary Team Management
Anti-Cancer Agents in Medicinal Chemistry Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Screening of Candidate Pathogenic Genes for Spontaneous Abortion Using Whole Exome Sequencing
Combinatorial Chemistry & High Throughput Screening Can the Use of HIV-1 Derived Gene Transfer Vectors for Clinical Application be Justified?
Current Gene Therapy Cratylia mollis Lectin: A Versatile Tool for Biomedical Studies
Current Bioactive Compounds